Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN has been in the news recently: Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, aiming to enhance genetics-based drug discovery and personal health services. The acquisition is expected to close in the third quarter of 2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
